Regulation of adropin by sitagliptin monotherapy in participants with newly diagnosed type 2 diabetes

HIGHLIGHTS

• who: Qiu Wang from the This was a phase, open-label, single-arm, interventional study to evaluate the effectiveness of sitagliptin for the treatment of newly diagnosed T DThe study was conducted in accordance with the Declaration of Helsinki and was registered on Cliniu200bcaltru200bials.u200bgov on, (registration number NCT04495881). The protocol was approved by the Ethics Committee of Beijing Chaoyang Hospital affiliated with Capital Medical University (2020-#-182). All enrolled participants provided written informed consent. Recruitment have published the research: Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes, in the Journal . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.